Filed under: Analyst upgrades and downgrades, Alcatel-LucentADS (ALU), Teva Pharm Indus ADR (TEVA)

MOST NOTEWORTHY: NCR Corp, Medivation and Teva Pharma were today’s noteworthy upgrades:

• Baird upgraded NCR Corp (NYSE: NCR) to Outperform from Neutral following its North American ATM managers survey that indicates a solid ATM environment and opportunity for margin improvement.
• Rodman & Renshaw upgraded Medivation (NASDAQ: MDVN) to Outperform from Market Perform citing valuation of the firm’s pipeline given recent catalyst of positive Phase II results in Huntington’s disease with lead candidate, Dimebon.
• Goldman added Teva Pharma (NASDAQ: TEVA) to its Conviction Buy List citing valuation, upcoming catalysts, and defensive characteristics.

OTHER UPGRADES:

• Marsh & McLennan (NYSE: MMC) was raised to Buy from Hold at Citigroup.
• RBC lifted Bankrate (NASDAQ: RATE) to Outperform from Sector Perform.
• Alcatel-Lucent (NYSE: ALU) was upgraded at WestLB to Hold from Sell.

Permalink | Email this | Comments

Via [bloggingstocks]

Share This

This entry was posted on Tuesday, July 8th, 2008 at 10:15 pm and is filed under Stocks Money News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.